Live
- Choose Smarter Financial Choices Over Impulsive Spending This Festive Season – Bandhan Mutual Fund
- Samsung Tops India’s Smartphone Market with 23% Value Share in Q3: Counterpoint Research
- Deloitte India opens entries for Enterprise Growth Awards 2024 to celebrate excellence in regional businesses
- Apeejay Surrendra Park Hotel Limited announces the opening of THE Lotus Palace Chettinad, a heritage hotel in Tamil Nadu
- Sharad Kelkar’s New Look Sparks Dhoni Buzz
- Drone technology is expected to revolutionise India’s marine fisheries sector
- Not every private resource can be considered a ‘material resource of the community’: SC
- Corruption in Karnataka's Excise Department
- AAP accused BJP MP Bansuri Swaraj of conspiring to disrupt the Chhath festivities in New Delhi
- US election: Battleground states in focus as voting begins in staggered fashion
Laurus Labs gets approval from FDA
Pharma major Laurus Labs received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its API Units 1 & 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.
Hyderabad: Pharma major Laurus Labs received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its API Units 1 & 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.
In the FDF segment, the company received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/ 300/ 400mg) for supply in GF funded projects.
Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).
This approval enables Laurus Labs to participate directly in GF and also In-Country tenders based on GF funding across Sub-Saharan African region along with our other ARV portfolio comprising of TLD (Tenofovir/ Lamivudine/ Dolutegravir 300/300/50mg), DTG (Dolutegravir 50mg) and ET (Emtricitabine/Tenofovir 200/300mg).
